Advanced Immunotherapy for Liver Cancer Treatment Launched in Egypt
This new medicine is now available at 22 specialised units nationwide, which provide free treatment to patients.
The Ministry of Health and Population has introduced a new immunotherapy drug to its treatment protocols for liver cancer. Using the active ingredient Tremelimumab/Durvalumab, this new medicine is now available at 22 specialised units nationwide, providing free treatment to patients and streamlining access to care.
The updated protocol, developed by the National Committee for Combating Hepatitis Viruses, integrates two types of immunotherapy alongside oral kinase inhibitors, offering a comprehensive approach to managing liver cancer. These therapies aim to improve survival rates and enhance the quality of life for patients.
Early detection remains a cornerstone of the fight against liver cancer. Over 119,000 patients with liver cirrhosis have received diagnostic services, with 592 treated using immunotherapy and nearly 5,000 receiving kinase inhibitors. Regular screenings, including ultrasounds and tumour tests, are conducted every four months at 58 centres across the country to identify liver tumours in their earliest stages.
Patients with confirmed diagnoses are quickly referred to specialised tumour treatment centers for immediate care. Additionally, healthcare providers across hepatitis virus units have been trained on the latest protocols to ensure consistent, high-quality treatment.
